BIAF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	112 089
Average Volume	230 495
Market Cap	27.75M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.65
ATR14	$0.0280 (1.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Zannes Maria	Buy	64 848	Common Stock
2024-04-08	Zannes Maria	Sell	28 264	Common Stock
2024-04-08	Zannes Maria	Sell	64 848	Stock Option (right to buy)
2024-04-04	Zannes Timothy P	Buy	64 848	Common Stock
2024-04-04	Zannes Timothy P	Sell	29 031	Common Stock

INSIDER POWER
27.67
Last 96 transactions
Buy: 1 352 288 \| Sell: 1 333 345

Volume Correlation

Long: -0.22 (neutral)

Short: 0.97 (very strong)

Signal:(53.937) Expect same movement, but be aware

bioAffinity Technologies, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

bioAffinity Technologies, Correlation - Currency/Commodity

0.03
( neutral )

0.34
( neutral )

0.00
( neutral )

-0.53
( weak negative )

-0.60
( weak negative )

0.37
( neutral )

bioAffinity Technologies, Financials

Annual	2023
Revenue:	$2.53M
Gross Profit:	$542 023 (21.40 %)
EPS:	$-0.910

Q4	2023
Revenue:	$2.21M
Gross Profit:	$399 710 (18.06 %)
EPS:	$-0.260

Q3	2023
Revenue:	$298 484
Gross Profit:	$223 780 (74.97 %)
EPS:	$-0.260

Q2	2023
Revenue:	$19 738.00
Gross Profit:	$18 504.00 (93.75 %)
EPS:	$-0.200

Financial Reports:

No articles found.

bioAffinity Technologies,

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.